Sun Pharmaceutical Industries has agreed to pay $485 million to settle an antitrust litigation for allegedly delaying generic versions of three drugs in the US.
Sun Pharma and its US-based subsidiary, Ranbaxy Inc., have signed a binding agreement with two plaintiff groups to settle claims regarding the antitrust litigation, the company said in an exchange filing.
The matter is related to alleged conduct by Ranbaxy Laboratories, before its acquisition by Sun Pharma and deals with application for three generic drugs: Hypertension drug Diovan,heartburn treatment Nexium, and antiviral Valcyte, , the company said.
The settlement covers multiple antitrust, consumer protection, and civil RICO class actions in connection with these generic drugs. “With a view to resolve this dispute and avoid uncertainty.”
The settlement agreement, on execution, will ensure that all allegations against it, “which it has denied, not conceded and not admitted, do not survive and stand extinguished”, Sun Pharmaceuticals said.
Sun Pharmaceuticals has had previous run-ins with antitrust law, including a 2017 case involving pharmaceutical rival Mylan, accused conspiring to raise the price of generic asthma medicine. The same union also filed another suit for similar charges against Mylan and Sandoz for colluding to boost the cost of another generic asthma medicine.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Walmart Withdraws and Refiles Antitrust Review Application for Vizio Acquisition
Mar 28, 2024 by
CPI
Apple Prevails in Dismissal of Crypto-Payment Antitrust Lawsuit
Mar 27, 2024 by
CPI
Amazon Fined in Poland for Misleading Customers
Mar 27, 2024 by
CPI
Credit Card Rewards Under Threat as Visa, Mastercard Settlement Impacts Swipe Fees
Mar 27, 2024 by
CPI
UK Fashion Giants Commit to Honest Environmental Claims
Mar 27, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI